Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)

Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.

Here's Why You Should Add RMD Stock to Your Portfolio Now

Greenbrier Companies

InterDigital

Leidos Hld

Walmart

Trump's re-election and the Fed rate cut bring back the lure for dividend investing. We have highlighted five solid picks that promise growth.

5 Dividend Growth Stocks to Buy on Trump Win & Fed Rate Cut

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA.

ResMed Announces Participation in the UBS Global Healthcare Conference

ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why ResMed (RMD) is a Strong Growth Stock

Accenture Plc

Amphenol

Domino's Pizza

Elevance Health Inc

Global Payments

Intuit

Lam Research

Mastercard

Microchip Technology

MSCI

Nordson

Rollins

SPDR S&P 500 ETF Trust

UnitedHealth Group

Vanguard Dividend Appreciation ETF

Zoetis

The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.

My Top 15 High-Growth Dividend Stocks For November 2024

Apogee Enterprises

Coastal Financial Corp

Kirby

Limbach Holdings

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy RMD, CCB, KEX, APOG and LMB.

5 Low-Leverage Stocks to Buy Ahead of Big Tech Earnings Releases

Royal Philips

Investors looking for stocks in the Medical - Products sector might want to consider either Royal Philips (PHG) or ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

PHG vs. RMD: Which Stock Should Value Investors Buy Now?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?

Carpenter Technology

JPMorgan Chase & Co

On Holding AG

S&P 500 giant JPMorgan Chase has been hovering near a buy point since a Q3 earnings beat. Several stocks are in or near buy zones.

S&P 500 Giant Leads 5 Stocks Near Buy Points

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.

Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst

RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand

Lennox International

Tractor Supply

Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends.

My 3 Favorite Stocks to Buy Right Now

ResMed Inc. (NYSE:RMD ) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Low - JPMorgan Saul Hadassin - Barrenjoey Capital Anthony Petrone - Mizuho Daniel Hurren - MST Marquee Mike Matson - Needham & Company Brett Fishbin - KeyBanc Capital Markets Suraj Kalia - Oppenheimer Lyanne Harrison - Bank of America Andrew Paine - CLSA Operator Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.

ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript

The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago.

ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment.

ResMed beats quarterly profit estimates on strong demand for its sleep apnea devices

ResMed stock bounded higher late Thursday after the CPAP-maker shrugged off worries popular weight-loss drugs would hammer its top line.

ResMed Adds To Its Recent Sprint, Shrugging Off Worries Tied To Obesity Drugs

NetApp

Travelers

Trane Technologies plc

Leidos Holdings, NetApp, ResMed, Trane Technologies and Travelers could be compelling picks for investors looking for dividend stocks.

5 Top Dividend Stocks That Promise Substantial Growth

Besides Wall Street's top -and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why

RMD's robust mask business and efforts to boost its SaaS business are encouraging.

News for ResMed Stock (RMD)